Hong Kong Sanatorium & Hospital IVM: Indications & Contraindications for Egg Quality Issues

Opening: Real Consultation Scenario

Consultation Scenario · A 34-year-old PCOS patient, AMH 8.6 ng/mL, antral follicle count >20 per side, with a history of OHSS tendency in two previous ovarian stimulations, uneven follicle development, and ultimately only a few mature eggs retrieved. She came to the Sanatorium Hospital Reproductive Center with her examination reports and asked a direct question: “Is there a problem with my egg quality? Can IVM help me?”

A Direct Answer to the Question

What Types of Egg Quality Issues is IVM Suitable For?

IVM (In Vitro Maturation) primarily addresses a specific type of quality issue: oocyte maturation disorder, rather than the broad concept of "poor egg quality." Specifically, it is suitable for the following situations:

• Arrested follicle development in PCOS patients — Many follicles but inability to complete the final maturation process.
• Low oocyte maturation rate during ovarian stimulation — Low proportion of mature eggs retrieved after conventional stimulation.
• History of OHSS or high risk of OHSS — High risk with conventional stimulation protocols.
• Hypersensitivity to ovarian stimulation medications — Ovarian hyper-response even with low doses.

For these conditions, IVM collects immature oocytes and matures them in a laboratory environment that simulates the body, avoiding the risks of high-dose stimulation and solving the problem of oocytes failing to mature in vivo.

B Why This Problem Occurs

Mechanism of Oocyte Maturation Disorder in PCOS Patients

The root cause of egg quality issues in PCOS patients lies in an abnormal follicular microenvironment. Elevated LH levels, insulin resistance, and abnormal androgen levels cause follicles to arrest at the antral stage, preventing completion of the final maturation process. This is not a "structural defect" of the oocyte itself, but rather impaired maturation mechanisms.

During conventional IVF stimulation, PCOS patients often over-respond to gonadotropins, are prone to OHSS, and experience asynchronous follicle development, resulting in low oocyte yield and suboptimal maturation rates. IVM bypasses the bottleneck of in vivo maturation, completing the process in the laboratory while eliminating the risk of OHSS.

C How Doctors View It

How Reproductive Specialists Assess IVM Suitability

When evaluating IVM protocols, reproductive doctors at Sanatorium Hospital focus on the following indicators:

• Antral Follicle Count (AFC) — Whether the number of antral follicles per ovary is ≥ 10.
• AMH Level — Whether it is elevated (typically > 4.0 ng/mL suggests PCOS tendency).
• History of response to ovarian stimulation — Whether OHSS or low oocyte maturation rate has occurred.
• Age — Under 35 years is the most suitable age range.
• Need for genetic testing — If PGT is required, IVM may not be the first choice.

Doctors combine these indicators for a comprehensive assessment and clearly inform patients of the expected outcomes and limitations of IVM.

D Differences Across Age Groups

IVM Suitability Differences Across Age Groups

Age Group	IVM Suitability	Primary Reason
≤ 35 years	Suitable	High rate of normal oocyte chromosomes, relatively ideal culture success rate; ideal candidates for IVM.
35 – 38 years	Considerable	Age-related decline in egg quality begins; if maturation disorder is the main issue, it can still be attempted, but expectations should be lowered.
> 38 years	Generally not recommended	Significantly increased rate of oocyte chromosomal abnormalities; IVM cannot improve chromosomal quality, and culture failure rate increases.

E Differences Between Hospitals - Integrated as Supplementary Content

Distinctive Aspects of Sanatorium Hospital's IVM Platform

IVM culture systems vary among reproductive centers, primarily in: culture media formulation, culture time window, criteria for oocyte retrieval timing, and accumulated experience. The Sanatorium Hospital Reproductive Center was an early adopter of IVM technology in Hong Kong. Its culture system has been optimized through years of clinical practice, providing a stable maturation rate for immature oocytes. However, this does not mean IVM success rates can surpass conventional IVF — in terms of live birth rates, IVM remains lower than conventional IVF, a characteristic of the technology itself, not something a single hospital can change.

F Most Easily Overlooked Details

Most Easily Overlooked Details

The key to successful IVM culture lies in the culture media formulation and timing control. The following details are often overlooked:

• Timing of oocyte retrieval — Whether minimal stimulation is needed before IVM retrieval, the follicle diameter criteria (typically 10–14 mm), and the culture duration after retrieval (24–48 hours) all affect the final maturation rate.
• Culture media composition — Different media have varying capacities to support immature oocytes. Sanatorium Hospital uses a specific optimized formulation, but individual results may still vary.
• Criteria for oocyte maturation — Extrusion of the first polar body is the gold standard for maturity, but some oocytes may exhibit asynchrony between cytoplasmic and nuclear maturation.

G Common Pitfalls

Common Cognitive Misconceptions

H Actual Procedure

Specific Procedure of Sanatorium Hospital IVM

The basic steps of an IVM cycle are divided into the following stages:

• ① Initial Consultation & Assessment — Reproductive doctor consultation, ultrasound, hormone panel (FSH, LH, E2, etc.), AMH, AFC, semen analysis, and other baseline tests.
• ② Protocol Planning — Determining whether to proceed with an IVM protocol based on assessment results, followed by signing informed consent.
• ③ Cycle Preparation — Natural cycle monitoring or minimal stimulation (low-dose HMG or FSH, typically for 3–5 days).
• ④ Oocyte Retrieval Surgery — Retrieval when follicles reach 10–14 mm in diameter; retrieved oocytes are immature (GV or MI stage).
• ⑤ Laboratory Culture — Immature oocytes are placed in specialized IVM culture medium and cultured at 37°C, 6% CO₂ for 24–48 hours.
• ⑥ Maturity Assessment — Observation of first polar body extrusion to confirm oocyte maturity (MII stage).
• ⑦ ICSI Fertilization — Performing ICSI on mature oocytes.
• ⑧ Embryo Culture — Fertilized oocytes are cultured further to the cleavage or blastocyst stage.
• ⑨ Embryo Transfer — Selecting 1–2 high-quality embryos for transfer; remaining embryos can be cryopreserved.
• ⑩ Luteal Phase Support — Luteal support (progesterone) after transfer; pregnancy test 12–14 days post-transfer.

The entire IVM cycle from initiation to transfer takes approximately 2–4 weeks, slightly shorter than a conventional IVF cycle, primarily due to the reduced duration of ovarian stimulation.

Supplementary Timeline

IVM Cycle Timeline Reference

Stage	Approximate Duration
Initial Assessment & Tests	1 – 2 weeks (including waiting for reports)
Cycle Monitoring / Minimal Stimulation	5 – 10 days
Retrieval → Lab Culture → ICSI	2 – 3 days
Embryo Culture to Transfer	3 – 6 days
Luteal Support Post-Transfer → Pregnancy Test	12 – 14 days

N Suitable Candidates

Who is Suitable for IVM?

• PCOS patients (especially those with arrested follicle development or excessive response to stimulation medications).
• Oocyte maturation disorder — Low oocyte maturation rate in previous stimulations despite adequate follicle numbers.
• High risk of OHSS — Including history of OHSS, elevated AMH, or high AFC.
• Hypersensitivity to ovarian stimulation medications — Ovarian hyper-response even with low doses.
• Cases requiring avoidance of high-dose estrogen exposure — e.g., history of estrogen-sensitive tumors.

O Non-Suitable Candidates

Who is Not Suitable for IVM?

• Severely diminished ovarian reserve (DOR, AMH < 1.0 ng/mL, AFC < 5).
• Women over 40 years old — High rate of oocyte chromosomal abnormalities; IVM culture cannot improve this.
• Cases requiring PGT genetic testing — IVM may yield fewer embryos, increasing biopsy risk.
• Severe male factor infertility — When ICSI is needed but IVM culture success rates are low, the overall benefit is suboptimal.
• Severe endometrial pathology or untreated hydrosalpinx — Uterine and tubal issues need to be addressed first.

P Frequently Asked Questions

Frequently Asked Questions

Special Situations

Managing Special Situations

The following special situations require individualized management:

• Previous IVM culture failure — The reasons for failure need to be analyzed, which may involve culture media selection, timing of retrieval, oocyte factors, etc. After adjusting the protocol, a repeat attempt can be considered.
• PCOS with insulin resistance — It is recommended to undergo 3–6 months of metabolic management (metformin, lifestyle intervention) before an IVM cycle to improve the follicular microenvironment.
• Few embryos obtained after IVM — Consider a cumulative cycle strategy or cross-comparison with conventional IVF before making a decision.

Practitioner Insight / Doctor's Perspective

Practitioner Insight

In clinical assisted reproduction, IVM has always held a position of "useful but not first-line." It is not a technology meant to replace conventional IVF, but rather a safer, gentler path for a specific population. The Sanatorium Hospital Reproductive Center takes a cautious approach to IVM: strictly screening suitable candidates, fully informing them of expectations, neither exaggerating results nor concealing risks.

Based on clinical data, the incidence of OHSS in PCOS patients choosing IVM is zero, compared to approximately 3%–8% in conventional IVF (higher in the PCOS population). This is the core advantage of IVM. However, the live birth rate per oocyte retrieval cycle for IVM is about 60%–70% of that for conventional IVF, and patients need to have a clear understanding of this.

Conclusion: Doctor's Advice Risk Reminder Knowledge Graph Tags (Visual Aid, Non-Interactive)